NCT06122181View on ClinicalTrials.gov

Study of HS-10384 in Participants of Chinese Postmenopausal Women

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 12, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

September 30, 2024

Conditions
Vasomotor Symptoms
Interventions
DRUG

HS-10384 tablets

Multiple dosing of HS-10384 orally in a fasting state

DRUG

HS-10384-matched placebo tablets

Multiple dosing of HS-10384-matched placebo orally in a fasting state

Trial Locations (1)

100000

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY